Scholar Rock (SRRK) Expected to Announce Earnings on Thursday

Scholar Rock (NASDAQ:SRRK) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Scholar Rock to post earnings of ($0.82) per share and revenue of $5.00 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same quarter last year, the business posted ($0.64) EPS. On average, analysts expect Scholar Rock to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Scholar Rock Stock Up 1.4%

SRRK stock opened at $47.13 on Wednesday. The firm has a market cap of $5.62 billion, a PE ratio of -13.74 and a beta of 0.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.95 and a current ratio of 6.95. The firm’s fifty day moving average is $46.16 and its 200 day moving average is $42.74. Scholar Rock has a one year low of $27.07 and a one year high of $51.63.

Wall Street Analysts Forecast Growth

SRRK has been the topic of several research analyst reports. Raymond James Financial reiterated a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday, March 3rd. Piper Sandler lifted their target price on shares of Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a research report on Wednesday, March 4th. Citigroup lifted their target price on shares of Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Canaccord Genuity Group initiated coverage on shares of Scholar Rock in a research report on Monday, April 20th. They issued a “buy” rating and a $62.00 target price on the stock. Finally, UBS Group initiated coverage on shares of Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price on the stock. Five investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Scholar Rock presently has a consensus rating of “Buy” and a consensus price target of $55.40.

Insiders Place Their Bets

In other news, insider Akshay Vaishnaw sold 12,246 shares of Scholar Rock stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $607,034.22. Following the sale, the insider owned 630,542 shares in the company, valued at $31,255,966.94. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Keith Woods sold 10,220 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $506,605.40. Following the completion of the transaction, the chief operating officer directly owned 620,055 shares in the company, valued at approximately $30,736,126.35. This represents a 1.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 102,736 shares of company stock valued at $4,977,900. 13.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently modified their holdings of the business. Blair William & Co. IL purchased a new position in shares of Scholar Rock in the fourth quarter worth about $441,000. Prudential Financial Inc. purchased a new position in shares of Scholar Rock in the second quarter worth about $364,000. Tower Research Capital LLC TRC lifted its stake in shares of Scholar Rock by 288.4% in the second quarter. Tower Research Capital LLC TRC now owns 9,115 shares of the company’s stock worth $323,000 after buying an additional 6,768 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Scholar Rock in the fourth quarter worth about $308,000. Finally, Virtus Investment Advisers LLC lifted its stake in shares of Scholar Rock by 66.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,676 shares of the company’s stock worth $250,000 after buying an additional 2,261 shares in the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).